Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1369-1381

  Arriaga, Juan M ^a,b   Greco, Angela ^a,b,c,d   Mordoh, José ^a   Bianchini, Michele ^a  

^a Instituto Médico Especializado Alexander Fleming   (Argentina)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^c INSTITUTO ALEXANDER FLEMING   (Argentina)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; FLUOROURACIL; FLUOZIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; METALLOTHIONEIN; METALLOTHIONEIN 1G; OXALIPLATIN; PROTEIN P53; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZINC; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; MT1G PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME REPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ZINC METABOLISM; ANIMAL; CELL DEATH; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; MALE; METALLOTHIONEIN; NF-KAPPA B; PROTEIN TRANSPORT; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINC;

EID: 84899800704     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0944     Document Type: Article

References (51)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005;23:4545-52.
3. Bell SG, Vallee BL. The metallothionein/thionein system: an oxidoreductive metabolic zinc link. Chembiochem 2009;10:55-62.
4. Pedersen M, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 2009;44:29-64.
5. Eckschlager T, Adam V, Hrabeta J, Figova K, Kizek R. Metallothioneins and cancer. Curr Protein Pept Sci 2009;10:360-75.
6. Chun JH, Kim HK, Kim E, Kim IH, Kim JH, Chang HJ, et al. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 2004;64:4703-6
7. Yap X, Tan HY, Huang J, Lai Y, Yip GW, Tan PH, et al. Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 2009;217:563-70.
8. Papouli E, Defais M, Larminat F. Overexpression of metallothionein-II sensitizes rodent cells to apoptosis induced by DNA cross-linking agent through inhibition of NF-kappa B activation. J Biol Chem 2002;277:4764-9.
9. Robson T, Hall A, Lohrer H. Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene. Mutat Res 1992;274:177-85.
10. Feng W, Cai J, Pierce WM, Franklin RB, Maret W, Benz FW, et al. Metallothionein transfers zinc to mitochondrial aconitase through a direct interaction in mouse hearts. Biochem Biophys Res Commun 2005;332:853-8.
11. Meplan C, Richard MJ, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 2000;19:5227-36.
12. Janssen AM, van Duijn W, Oostendorp-Van De Ruit MM, Kruidenier L, Bosman CB, Griffioen G, et al. Metallothionein in human gastrointestinal cancer. J Pathol 2000;192:293-300.
13. Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, et al. Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. Hum Pathol 2012;43:197-208.
14. Arriaga JM, Bravo IA, Bruno L, Morales Bayo S, Hannois A, Sanchez Loria F, et al. Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B andC colorectal cancer. Hum Pathol 2012;43:1695-703.
15. Bozym RA, Chimienti F, Giblin LJ, Gross GW, Korichneva I, Li Y, et al. Free zinc ions outside a narrow concentration range are toxic to a variety of cells in vitro. Exp Biol Med 2010;235:741-50.
16. Cousins RJ, Liuzzi JP, Lichten LA. Mammalian zinc transport, trafficking, and signals. J Biol Chem 2006;281:24085-9.
17. Costello LC, Fenselau CC, Franklin RB. Evidence for operation of the direct zinc ligand exchange mechanism for trafficking, transport, and reactivity of zinc inmammalian cells. J Inorg Biochem2011;105:589-99.
18. Maret W. Zinc coordination environments in proteins as redox sensors and signal transducers. Antioxid Redox Signal 2006;8: 1419-41.
19. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011;10: 1679-89.
20. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, et al. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 2012;131: E562-8.
21. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, et al. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 2008;88:474-81.
22. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007;6:37-50.
23. Qiu T, Zhou L, Zhu W, WangT,WangJ, Shu Y, et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 2013;9:255-69.
24. Majumder S, Roy S, Kaffenberger T, Wang B, Costinean S, Frankel W, et al. Loss of metallothionein predisposes mice to diethylnitrosamineinduced hepatocarcinogenesis by activating NF-kappaB target genes. Cancer Res 2010;70:10265-76.
25. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008; 327:746-59.
26. Flis S, Gnyszka A, Spøawinśki J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 2009;387:336-41.
27. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 2009;125:463-73.
28. Wilson AJ, Chueh AC, Tögel L, Corner GA, Ahmed N, Goel S, et al. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 2010;70:609-20.
29. Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat 2011;125:55-63.
30. Guo R, Wu G, Li H, Qian P, Han J, Pan F, et al. Promoter methylation profiles between human lung adenocarcinoma multidrug resistant A549/cisplatin (A549/DDP) cells and its progenitor A549 cells. Biol Pharm Bull 2013;36:1310-6.
31. Cai L, Li XK, Song Y, Cherian MG. Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 2005;12:2753-63.
32. Jayaraman AK, Jayaraman S. Increased level of exogenous zinc induces cytotoxicity and up-regulates the expression of the ZnT-1 zinc transporter gene in pancreatic cancer cells. J Nutr Biochem 2011;22:79-88.
33. Sliwinski T, Czechowska A, Kolodziejczak M, Jajte J, Wisniewska- JarosinskaM,Blasiak J. Zinc salts differentially modulateDNAdamage in normal and cancer cells. Cell Biol Int 2009;33:542-7.
34. Roosen N, Doz F, Yeomans KL, Dougherty DV, Rosenblum ML. Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine. Cancer Chemother Pharmacol 1994;34:385-92.
35. Makhov P, Kutikov A, Golovine K, Uzzo RG, Canter DJ, Kolenko VM. Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: potential implication for prostate cancer therapy. Prostate 2011;71:1413-9.
36. Feng P, Li TL, Guan ZX, Franklin RB, Costello LC. Effect of zinc on prostatic tumorigenicity in nude mice. Ann N Y Acad Sci 2003;1010: 316-20.
37. Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C, et al. Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res 2009;28:84.
38. Huesca M, Lock LS,Khine AA, Viau S, Peralta R, Cukier IH, et al. Anovel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis. Mol Cancer Ther 2009;8:2586-96.
39. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res 2005;65:3389-95.
40. Magda D, Lecane P, Miller RA, Lepp C, Miles D, Mesfin M, et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005;65:3837-45.
41. Magda D, Lecane P, Wang Z, Hu W, Thiemann P, MaX, et al. Synthesis and anticancer properties of water-soluble zinc ionophores. Cancer Res 2008;68:5318-25.
42. Floersheim GL, Christ A, Koenig R, Racine C, Gudat F. Radiationinduced lymphoid tumors and radiation lethality are inhibited by combined treatment with small doses of zinc aspartate and WR 2721. Int J Cancer 1992;52:604-8.
43. Eby GA. Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation-a case history and hypothesis. Med Hypotheses 2005;64:1124-6.
44. Lin YS, Lin LC, Lin SW. Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis. Laryngoscope 2009;119: 1348-52.
45. Dalla Pozza E, Donadelli M, Costanzo C, Zaniboni T, Dando I, Franchini M, et al. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Free Radic Biol Med 2011;50:926-33.
46. Kelly EJ, Quaife CJ, Froelick GJ, Palmiter RD. Metallothionein I and II protect against zinc deficiency and zinc toxicity in mice. J Nutr 1996;126:1782-90.
47. Maret W. Metals on the move: zinc ions in cellular regulation and in the coordination dynamics of zinc proteins. Biometals 2011;24:411-8.
48. Beyersmann D, Haase H. Functions of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals 2001;14:331-41.
49. Michalczyk AA, Ackland ML. hZip1 (hSLC39A1) regulates zinc homoeostasis in gut epithelial cells. Genes Nutr 2013;8:475-86.
50. Feldman SL, Failla ML, Cousins RJ. Degradation of rat liver metallothioneins in vitro. Biochim Biophys Acta 1978;544:638-646.
51. Petering DH, Zhu J, Krezoski S, Meeusen J, Kiekenbush C, Krull S, et al. Apo-metallothionein emerging as a major player in the cellular activities of metallothionein. Exp Biol Med 2006;231:1528-34.